Cargando…
Viable SARS-CoV-2 shedding under remdesivir and dexamethasone treatment
Autores principales: | Yoon, Jin Gu, Yoo, Jin Sae, Lee, Jungmin, Hyun, Hak-Jun, Seong, Hye, Noh, Ji Yun, Cheong, Hee Jin, Kim, Woo Joo, Kim, Young Rong, Heo, Jung Yeon, Bae, Joon-Yong, Cui, Chunguang, Lee, Sohyun, Park, Man-Seong, Song, Joon Young |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The British Infection Association. Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957381/ https://www.ncbi.nlm.nih.gov/pubmed/35351541 http://dx.doi.org/10.1016/j.jinf.2022.03.022 |
Ejemplares similares
-
Prognostic factors of 30-day mortality in patients with COVID-19 pneumonia under standard remdesivir and dexamethasone treatment
por: Choi, Yu Jung, et al.
Publicado: (2022) -
Clinical scoring system to predict viable viral shedding in patients with COVID-19
por: Kang, Sung Woon, et al.
Publicado: (2022) -
Asymptomatic infection and atypical manifestations of COVID-19: Comparison of viral shedding duration
por: Noh, Ji Yun, et al.
Publicado: (2020) -
Diagnostic usefulness of subgenomic RNA detection of viable SARS-CoV-2 in patients with COVID-19
por: Kim, Ji Yeun, et al.
Publicado: (2022) -
Viral Shedding and Environmental Cleaning in Middle East Respiratory Syndrome Coronavirus Infection
por: Song, Joon Young, et al.
Publicado: (2015)